Noticias en inglés por niveles

Breakthrough Drug Nearly Doubles Survival in Pancreatic Cancer, Cutting Death Risk by 60 Percent

The experimental drug daraxonrasib delivered what doctors described as unprecedented results at the 2026 American Society of Clinical Oncology annual meeting, nearly doubling survival time for patients with advanced pancreatic cancer and reducing the risk of death by 60 percent. The drug targets a protein called KRAS found in more than 90 percent of pancreatic tumors, a molecular target that had eluded effective treatment for over four decades.